TNF Pharmaceuticals/$TNFA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About TNF Pharmaceuticals
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine.
Ticker
$TNFA
Sector
Primary listing
Employees
6
Headquarters
Website
TNFA Metrics
BasicAdvanced
$7.1M
-
-$159.52
2.28
-
Price and volume
Market cap
$7.1M
Beta
2.28
52-week high
$5.00
52-week low
$3.24
Financial strength
Current ratio
0.928
Quick ratio
0.687
Profitability
Management effectiveness
Return on assets (TTM)
-24.00%
Return on equity (TTM)
-115.40%
Valuation
Price to book
0.23
Price to tangible book (TTM)
-0.22
Price to free cash flow (TTM)
-0.029
Free cash flow yield (TTM)
-3,497.73%
Free cash flow per share (TTM)
-141.293
Growth
Earnings per share change (TTM)
-86.64%
3-year earnings per share growth (CAGR)
-50.30%
TNFA News
AllArticlesVideos
TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Business Wire4 days ago
TNF Pharmaceuticals Announces Closing of $7 Million Private Placement
Business Wire1 week ago
TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications
Business Wire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for TNF Pharmaceuticals stock?
TNF Pharmaceuticals (TNFA) has a market cap of $7.1M as of September 12, 2025.
What is the P/E ratio for TNF Pharmaceuticals stock?
The price to earnings (P/E) ratio for TNF Pharmaceuticals (TNFA) stock is 0 as of September 12, 2025.
Does TNF Pharmaceuticals stock pay dividends?
No, TNF Pharmaceuticals (TNFA) stock does not pay dividends to its shareholders as of September 12, 2025.
When is the next TNF Pharmaceuticals dividend payment date?
TNF Pharmaceuticals (TNFA) stock does not pay dividends to its shareholders.
What is the beta indicator for TNF Pharmaceuticals?
TNF Pharmaceuticals (TNFA) has a beta rating of 2.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.